U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Cangene BioPharma, LLC - 630316 - 10/04/2023
  1. Warning Letters

CLOSEOUT LETTER

Cangene BioPharma, LLC MARCS-CMS 630316 —

Delivery Method:
ELECTRONIC DELIVERY/READ RECEIPT
Product:
Drugs
Recipient:
Recipient Name
Mr. David Fidler
Recipient Title
Vice President, Manufacturing Operations, General Manager
Cangene BioPharma, LLC

1111 S. Paca St.
Baltimore, MD 21230
United States

fidlerd@ebsi.com
Issuing Office:
Division of Pharmaceutical Quality Operations I

United States

Dear Mr. Fidler:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter [CMS #630316], dated August 10, 2022. Based on our evaluation, it appears that you have adequately addressed the violations contained in this Warning Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Respectfully,
/S/
Lisa Harlan
Program Division Director
U.S. Food and Drug Administration
Office of Pharmaceutical Quality Operations Division I

Back to Top